Cart
sales@molnova.com
SU-9516 (b)
CAS No. 666837-93-0
SU-9516 (b)( —— )
Catalog No. M22990 CAS No. 666837-93-0
SU9516 is a selectively potent ATP-competitive inhibitor of CDKs.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 120 | In Stock |
|
| 10MG | 156 | In Stock |
|
| 25MG | 234 | In Stock |
|
| 50MG | 304 | In Stock |
|
| 100MG | 396 | In Stock |
|
| 500MG | 888 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSU-9516 (b)
-
NoteResearch use only, not for human use.
-
Brief DescriptionSU9516 is a selectively potent ATP-competitive inhibitor of CDKs.
-
DescriptionSU9516 is a selectively potent ATP-competitive inhibitor of CDKs.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorCDK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number666837-93-0
-
Formula Weight241.24
-
Molecular FormulaC13H11N3O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C1NC2=C(C=C(OC)C=C2)C1=CC3=CN=CN3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Collins I , Garrett M D . Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors[J]. Current Opinion in Pharmacology, 2005, 5(4):366-373.
molnova catalog
related products
-
NU-2058
An ATP-competitive inhibitor of CDK1 and CDK2 with Ki of 5 uM and 12 uM respectively; inhibits human tumor cells with a mean GI50 of 13±7 uM.
-
BS-194
BS-194 is a potent, selective, orally bioactive CDK2 inhibitor with IC50 of 2.4 nM, displays 140-fold selectivity over CDK7 (IC50=378 nM); weakly inhibits CDK1, CDK5, CDK7, and CDK9 with IC50 of 30, 30, 250, and 90 nM.
-
CDK4-IN-1
CDK4 inhibitor is a novel and specific CDK4/Cyclin D1 inhibitor with an IC50 of 10 nM.
